drugset / Trial / NCT05611853
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1/2 trial to study the safety, pharmacokinetics and preliminary efficacy of BN301 given intravenously every 3 weeks.
Timeline
- Start
- 2022-11-25
- Primary completion
- 2023-12-25
- Completion
- 2023-12-25
Outcome
Outcome not reported
Stopped: “Due to company decision”